Drug Trial Radar · NCT04221945
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,060
Actual
Start
May 12, 2020
Primary completion
Jan 7, 2025
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Jan 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival. Once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.
Conditions
- Uterine Cervical Neoplasms
Interventions
PembrolizumabBiological
IV infusion
Placebo for pembrolizumabDrug
IV infusion
CisplatinDrug
IV infusion
External Beam Radiotherapy (EBRT)Radiation
Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
BrachytherapyRadiation
Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the InvestigatorTime frame: Up to approximately 55 months
- Overall Survival (OS)Time frame: Up to approximately 55 months
Locations
176 sites in 30 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute - Biltmore ( Site 8009)
Phoenix, Arizona
UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0027)
Los Angeles, California
Hoag Memorial Hospital Presbyterian ( Site 0038)
Newport Beach, California
UC Davis Comprehensive Cancer Center ( Site 0017)
Sacramento, California
University of Colorado Health Sciences Center and Hospital ( Site 0028)
Denver, Colorado
Smilow Cancer Center at Yale-New Haven ( Site 0023)
New Haven, Connecticut
AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 0009)
Orlando, Florida
Parkview Research Center at Parkview Regional Medical Center ( Site 0026)
Fort Wayne, Indiana
University of Kentucky Markey Cancer Center ( Site 0015)
Lexington, Kentucky
Our Lady of the Lake Regional Medical Center. ( Site 0031)
Baton Rouge, Louisiana
Women's Cancer Care ( Site 0039)
Covington, Louisiana
Karmanos Cancer Institute ( Site 0018)
Detroit, Michigan
Minnesota Oncology Hematology, PA ( Site 8007)
Minneapolis, Minnesota
University of New Mexico Comprehensive Cancer Center-Clinical Research Office ( Site 0019)
Albuquerque, New Mexico
University of North Carolina at Chapel Hill ( Site 0025)
Chapel Hill, North Carolina
Sanford Bismarck Medical Center ( Site 0046)
Bismarck, North Dakota
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
Columbus, Ohio
Willamette Valley Cancer Institute and Research Center ( Site 8000)
Eugene, Oregon
Legacy Good Samaritan Medical Center ( Site 0013)
Portland, Oregon
Allegheny Health Network West Penn Hospital-Gynecologic Oncology ( Site 0030)
Pittsburgh, Pennsylvania
Hollings Cancer Center ( Site 0007)
Charleston, South Carolina
Sanford Gynecology Oncology ( Site 0003)
Sioux Falls, South Dakota
Texas Oncology-Austin Central ( Site 8006)
Austin, Texas
Texas Oncology-Fort Worth Cancer Center ( Site 8001)
Fort Worth, Texas
Texas Oncology-San Antonio Medical Center ( Site 8002)
San Antonio, Texas
Texas Oncology-The Woodlands ( Site 8003)
The Woodlands, Texas
UVA Health System ( Site 0005)
Charlottesville, Virginia
Virginia Commonwealth University ( Site 0024)
Richmond, Virginia
Westmead Hospital ( Site 0973)
Westmead, New South Wales, Australia
Royal Brisbane and Women s Hospital ( Site 0972)
Herston, Queensland, Australia
Monash Health-Monash Medical Centre ( Site 0970)
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre ( Site 0971)
Melbourne, Victoria, Australia
St John of God Subiaco Hospital ( Site 0969)
Subiaco, Western Australia, Australia
Medizinische Universität Wien ( Site 0567)
Vienna, State of Vienna, Austria
Medizinische Universitat Graz ( Site 0569)
Graz, Styria, Austria
Medizinische Universitat Innsbruck ( Site 0566)
Innsbruck, Tyrol, Austria
UZA University Hospital Antwerp ( Site 0351)
Edegem, Antwerpen, Belgium
GZA Sint Augustinus ( Site 0356)
Wilrijk, Antwerpen, Belgium
C.I.U. Hopital Ambroise Pare ( Site 0353)
Mons, Hainaut, Belgium
OLV Ziekenhuis ( Site 0352)
Aalst, Oost-Vlaanderen, Belgium
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.